A total of six (23.1%) patients in cohort A2 and all patients in cohort C tested positive for at least one of the selected biomarkers of ARID1A, ATRX/DAXX, ATM, as assessed in liquid and/or tumour biopsies. This evidence concerns the gene ATRX and neoplasm.